Cargando…

Amantadine in Treatment of Dysthymia—The Pilot Case Series Study

Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzystanek, Marek, Martyniak, Ewa, Pałasz, Artur, Skałacka, Katarzyna, Chwalba, Artur, Wierzbiński, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301632/
https://www.ncbi.nlm.nih.gov/pubmed/37375844
http://dx.doi.org/10.3390/ph16060897
_version_ 1785064858671120384
author Krzystanek, Marek
Martyniak, Ewa
Pałasz, Artur
Skałacka, Katarzyna
Chwalba, Artur
Wierzbiński, Piotr
author_facet Krzystanek, Marek
Martyniak, Ewa
Pałasz, Artur
Skałacka, Katarzyna
Chwalba, Artur
Wierzbiński, Piotr
author_sort Krzystanek, Marek
collection PubMed
description Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. This justifies attempts to identify second-line drugs for the treatment of dysthymia. In an open and naturalistic case study, five patients diagnosed with dysthymia in whom at least one antidepressant treatment was ineffective were treated with amantadine. In the age- and gender-matched external control group, patients were treated with sertraline at 100 mg/day. Depressive symptoms were assessed using HDRS-17. Two men and three women were treated with 100 mg amantadine for 3 months with 3–5 months follow-up. After 1 month of treatment with amantadine, a significant reduction in the intensity of depressive symptoms was achieved in all patients, and the clinical improvement increased over the next 2 months of treatment. No deterioration in well-being was observed in any patient after discontinuation of amantadine. The effect of amantadine treatment was comparable to that of sertraline treatment in patients with dysthymia who improved with this drug. The present study indicates that amantadine is an effective and well-tolerated drug in the treatment of dysthymia. Amantadine may be associated with a quick improvement in symptoms in the treatment of dysthymia. Treatment with this drug seems to be associated with good tolerability and persistency of the therapeutic effect after the discontinuation of the treatment.
format Online
Article
Text
id pubmed-10301632
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103016322023-06-29 Amantadine in Treatment of Dysthymia—The Pilot Case Series Study Krzystanek, Marek Martyniak, Ewa Pałasz, Artur Skałacka, Katarzyna Chwalba, Artur Wierzbiński, Piotr Pharmaceuticals (Basel) Communication Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. This justifies attempts to identify second-line drugs for the treatment of dysthymia. In an open and naturalistic case study, five patients diagnosed with dysthymia in whom at least one antidepressant treatment was ineffective were treated with amantadine. In the age- and gender-matched external control group, patients were treated with sertraline at 100 mg/day. Depressive symptoms were assessed using HDRS-17. Two men and three women were treated with 100 mg amantadine for 3 months with 3–5 months follow-up. After 1 month of treatment with amantadine, a significant reduction in the intensity of depressive symptoms was achieved in all patients, and the clinical improvement increased over the next 2 months of treatment. No deterioration in well-being was observed in any patient after discontinuation of amantadine. The effect of amantadine treatment was comparable to that of sertraline treatment in patients with dysthymia who improved with this drug. The present study indicates that amantadine is an effective and well-tolerated drug in the treatment of dysthymia. Amantadine may be associated with a quick improvement in symptoms in the treatment of dysthymia. Treatment with this drug seems to be associated with good tolerability and persistency of the therapeutic effect after the discontinuation of the treatment. MDPI 2023-06-19 /pmc/articles/PMC10301632/ /pubmed/37375844 http://dx.doi.org/10.3390/ph16060897 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Krzystanek, Marek
Martyniak, Ewa
Pałasz, Artur
Skałacka, Katarzyna
Chwalba, Artur
Wierzbiński, Piotr
Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
title Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
title_full Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
title_fullStr Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
title_full_unstemmed Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
title_short Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
title_sort amantadine in treatment of dysthymia—the pilot case series study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301632/
https://www.ncbi.nlm.nih.gov/pubmed/37375844
http://dx.doi.org/10.3390/ph16060897
work_keys_str_mv AT krzystanekmarek amantadineintreatmentofdysthymiathepilotcaseseriesstudy
AT martyniakewa amantadineintreatmentofdysthymiathepilotcaseseriesstudy
AT pałaszartur amantadineintreatmentofdysthymiathepilotcaseseriesstudy
AT skałackakatarzyna amantadineintreatmentofdysthymiathepilotcaseseriesstudy
AT chwalbaartur amantadineintreatmentofdysthymiathepilotcaseseriesstudy
AT wierzbinskipiotr amantadineintreatmentofdysthymiathepilotcaseseriesstudy